Solubest raises $1.4m in internal round

Solubest’s technology enhances the solubility of drugs that combat AIDS-related and various other fungal infections.

Israeli start-up Solubest has raised $1.4 million from its previous investor, Alplex BV, the BioIsrael website reported last week. The money is slated use nanotechnology for development of active materials to treat various infectious diseases.

Solubest’s technology enhances the solubility of drugs that combat AIDS-related and various other fungal infections. Greater solubility of the material in the stomach and the bloodstream is designed to make the material more effective, making it possible to reduce dosages and curb side effects. Development of new drug delivery methods, which have been registered as patents, can also extend the patent period for each drug.

Chairman, and CEO Erwin Stern founded Rehovot-based Solubest in 2001. Solubest is a member of the Israeli Nanoparticles consortium. The company says it has signed agreements concerning its technology with major pharmaceutical firms in the US, Israel, and Europe.

Published by Globes [online] - www.globes.co.il - on February 9, 2003

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס